We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cancer Cells with p53 Mutations Have Phosphatidylinositol Signaling Molecules with Shortened Lipid Acyl Chains

By LabMedica International staff writers
Posted on 13 Jan 2015
Print article
Image: Molecular structure of phosphatidylinositol (Photo courtesy of Wikimedia Commons).
Image: Molecular structure of phosphatidylinositol (Photo courtesy of Wikimedia Commons).
A recent study showed that cancer cells with mutations in the p53 gene were distinguished by reduced-length fatty acid moieties in their cell membranes.

Phosphatidylinositol phosphate (PIP) second messengers relay growth cues via the cell membrane through the phosphorylation status of the inositol sugar, a signal transduction system that is deregulated in cancer. In contrast to PIP inositol head-group phosphorylation, changes in phosphatidylinositol (PI) lipid acyl chains in cancer have remained ill-defined.

Investigators at Cold Spring Harbor Laboratory (NY, USA) applied a mass-spectrometry-based method capable of unbiased high-throughput identification to quantify cellular PI acyl chain composition. Using this approach, they found that PI lipid chains represented a cell-specific fingerprint that was unperturbed by serum-mediated signaling in contrast to the inositol head group. Mutation of p53 resulted in PIs containing fatty acid moieties reduced in length by from two to four carbon atoms.

"What we would like to find out now," said senior author Dr. Lloyd Trotman, an associate professor at Cold Spring Harbor Laboratory, "is whether the p53-induced changes in the PI molecule are important in either making or maintaining the cancer state. If so, then in addition to p53 mutations, there may be other ways for cancer cells to generate the same or related changes. We will be looking for this in tissue samples from cancer patients."

The study was published in the December 24, 2014, online edition of the journal Cell Reports.

Related Links:

Cold Spring Harbor Laboratory


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more